Morgan Stanley Obs Eva Sa Transaction History

Morgan Stanley

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.14 - $0.21 $6,074 - $9,112	-43,391 Reduced 54.2%	36,661 $5,000
Q3 2022 Nov 14, 2022	BUY	$0.14 - $1.83 $2,477 - $32,385	17,697 Added 28.38%	80,052 $11,000
Q2 2022 Oct 27, 2022	SELL	$1.34 - $2.08 $23,692 - $36,776	-17,681 Reduced 22.09%	62,355 $100,000
Q2 2022 Aug 15, 2022	SELL	$1.34 - $2.08 $23,692 - $36,776	-17,681 Reduced 22.09%	62,355 $100,000
Q1 2022 Oct 27, 2022	BUY	$1.1 - $2.17 $19,449 - $38,367	17,681 Added 28.36%	80,036 $121,000
Q1 2022 May 13, 2022	BUY	$1.1 - $2.17 $4,412 - $8,703	4,011 Added 5.28%	80,036 $121,000
Q4 2021 Feb 14, 2022	SELL	$1.99 - $3.1 $120,542 - $187,779	-60,574 Reduced 44.34%	76,025 $151,000
Q3 2021 Nov 15, 2021	BUY	$2.47 - $3.34 $337,399 - $456,240	136,599 New	136,599 $425,000

88K

Ticker OBSV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,499,200
Description
ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin releasing hormone receptor antagonist that is in Phase III clinical trial for the treatment of pain associated with endometrio...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.